| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Jeffrey Finer
Also a director
Chief Executive Officer
Title from the Form 4 dated Nov 12, 2026
|
60 | Not stated | $2,933,339 | |
|
Gil M. Labrucherie
Chief Financial Officer
|
54 | Not stated | $3,240,351 | |
|
Liz Bhatt
President and Chief Operating Officer
|
58 | Not stated | $1,590,770 | |
|
Elizabeth Bhatt
President and COO
Title from the Form 4 dated Oct 15, 2026
|
Not stated | Not stated | Not reported | |
|
Jae B. Kim
Chief Medical Officer
|
56 |
Since 2024
2 years
|
Not reported | |
|
Samira Shaikhly
Chief People Officer
|
56 |
Since 2023
3 years
|
Not reported | |
|
Mark Wilson
Chief Legal Officer
|
55 |
Since 2026
this year
|
Not reported | |
|
Rajiv Patni
Chief Medical Officer
Title from the Form 4 dated Sep 8, 2026
|
Not stated | Not stated | Not reported | |
|
Uwe Klein
Senior Vice President, Biological Sciences
|
61 |
Since 2021
5 years
|
Not reported | |
|
Daniel Long
Senior Vice President, Drug Discovery
|
53 |
Since 2021
5 years
|
Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
The proxy filed Apr 30, 2026 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...